Sagimet Biosciences Inc. Retained Earnings
Sagimet Biosciences Inc. (SGMT) had Retained Earnings of -$370.95 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$370.95M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$357.00M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$346.35M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$336.78M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$370.95M 10-Q · filed 2026-08-11 |
| 2026-03-31 | -$357.00M 10-Q · filed 2026-05-12 |
| 2025-12-31 | -$346.35M 10-Q · filed 2026-08-11 |
| 2025-09-30 | -$336.78M 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$323.87M 10-Q · filed 2025-08-13 |
| 2025-03-31 | -$313.49M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$295.31M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$279.11M 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$264.49M 10-Q · filed 2024-08-14 |
| 2024-03-31 | -$256.37M 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$249.74M 10-K · filed 2025-03-12 |
| 2023-09-30 | -$241.59M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$235.24M 10-Q · filed 2023-08-21 |
| 2022-12-31 | -$221.87M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |